High Risks Adverse Events Associated with Trastuzumab Emtansine and Trastuzumab Deruxtecan for the Treatment of HER2-positive/mutated Malignancies: A Pharmacovigilance Study based on the FAERS Database.
Sign Up to like & getrecommendations! Published in 2023 at "Expert opinion on drug safety"
DOI: 10.1080/14740338.2023.2204228
Abstract: BACKGROUND T-DM1 and T-DXd are two promising antibody-drug conjugates for treating advanced HER2-positive breast cancer and HER2-mutated lung cancer. Understanding the differences in the adverse events (AEs) profile of both drugs may help clinicians make… read more here.
Keywords: her2 positive; faers database; treatment; adverse events ... See more keywords
Analysis of Adverse Reactions of Aspirin in Prophylaxis Medication Based on FAERS Database
Sign Up to like & getrecommendations! Published in 2022 at "Computational and Mathematical Methods in Medicine"
DOI: 10.1155/2022/7882277
Abstract: Objective As the most commonly used drug in the world, aspirin has shown benefits for myocardial infarction, stroke, and vascular death in many secondary prevention trials and their meta-analysis. The purpose of this study was… read more here.
Keywords: medication; adverse reactions; faers database; prophylaxis medication ... See more keywords
Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database
Sign Up to like & getrecommendations! Published in 2023 at "Drug, Healthcare and Patient Safety"
DOI: 10.2147/dhps.s391857
Abstract: Purpose The aim of this study was to characterize the frequency of adverse effects where delta-8 tetrahydrocannabinol (D8-THC) was identified as a possible suspect drug in the FDA Adverse Event Reporting System (FAERS) database. Methods… read more here.
Keywords: reporting system; suspect drug; event reporting; adverse event ... See more keywords
Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2023.1110575
Abstract: Background and purpose: Several clinical trials have indicated that the use of canagliflozin increases the risk of lower extremity amputation. Although the US Food and Drug Administration (FDA) has withdrawn its black box warning about… read more here.
Keywords: glucose transporter; osteomyelitis; canagliflozin; risk ... See more keywords